Compare BTBD & IMNN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BTBD | IMNN |
|---|---|---|
| Founded | 1987 | 1982 |
| Country | United States | United States |
| Employees | 188 | N/A |
| Industry | Restaurants | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.2M | 8.4M |
| IPO Year | N/A | 2000 |
| Metric | BTBD | IMNN |
|---|---|---|
| Price | $1.19 | $2.03 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $10.00 |
| AVG Volume (30 Days) | ★ 71.0K | 47.5K |
| Earning Date | 05-15-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.03 | $0.48 |
| 52 Week High | $5.59 | $9.32 |
| Indicator | BTBD | IMNN |
|---|---|---|
| Relative Strength Index (RSI) | 40.50 | 24.91 |
| Support Level | $1.15 | N/A |
| Resistance Level | $1.22 | $2.50 |
| Average True Range (ATR) | 0.06 | 0.15 |
| MACD | 0.03 | 0.00 |
| Stochastic Oscillator | 40.07 | 14.55 |
BT Brands Inc operates and owns a fast-food restaurant called Burger Time. Its offerings include a variety of burgers and other affordable items, including sides and soft drinks. The company owns and operates Keegan's Seafood Grille (Keegan's), a dine-in restaurant located in Florida; Pie In The Sky Coffee and Bakery (PIE), located in Massachusetts; and Schnitzel Haus, a German-themed restaurant located in Florida. The company's revenues are derived from the sale of food and beverages at its restaurants.
Imunon Inc is a clinical-stage biotechnology company focused on advancing a portfolio of treatments that harness the body's natural mechanisms to generate safe, effective and durable responses across a broad array of human diseases, constituting a differentiating approach from conventional therapies. It is developing its non-viral DNA technology across its modalities. The first modality, TheraPlas, is developed for the coding of proteins and cytokines in the treatment of solid tumors. The second modality, PlaCCine, is developed for the coding of viral antigens that can elicit an immunological response. The company's clinical program, IMNN-001, is a DNA-based immunotherapy for the localized treatment of ovarian cancer.